[{"id":"5d9e65c6-b900-41df-834e-6e18a16cdf9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT07470203","created_at":"2026-03-28T01:44:18.552Z","updated_at":"2026-03-28T01:44:18.552Z","phase":"","brief_title":"Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer","source_id_and_acronym":"NCT07470203","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Irene (pyrotinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/31/2026","start_date":" 03/31/2026","primary_txt":" Primary completion: 03/31/2029","primary_completion_date":" 03/31/2029","study_txt":" Completion: 09/30/2029","study_completion_date":" 09/30/2029","last_update_posted":"2026-03-13"},{"id":"70cc1b41-3bca-4660-a674-24287764e8ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT07094204","created_at":"2025-08-02T14:04:37.665Z","updated_at":"2025-08-02T14:04:37.665Z","phase":"Phase 1","brief_title":"A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors","source_id_and_acronym":"NCT07094204","lead_sponsor":"Astellas Pharma Inc","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 364","initiation":"Initiation: 07/31/2025","start_date":" 07/31/2025","primary_txt":" Primary completion: 11/30/2028","primary_completion_date":" 11/30/2028","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-07-30"},{"id":"dd30cd49-1fd8-43e7-b783-449eccebfd62","acronym":"","url":"https://clinicaltrials.gov/study/NCT07070713","created_at":"2025-07-19T14:10:13.961Z","updated_at":"2025-07-19T14:10:13.961Z","phase":"Phase 2","brief_title":"Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC","source_id_and_acronym":"NCT07070713","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Qibeian (iparomlimab/tuvonralimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/30/2025","start_date":" 07/30/2025","primary_txt":" Primary completion: 02/28/2028","primary_completion_date":" 02/28/2028","study_txt":" Completion: 08/30/2028","study_completion_date":" 08/30/2028","last_update_posted":"2025-07-17"},{"id":"e43e3d0d-a928-4113-b0cb-1cb1cbe5fa52","acronym":"","url":"https://clinicaltrials.gov/study/NCT07044908","created_at":"2025-07-05T14:01:51.038Z","updated_at":"2025-07-05T14:01:51.038Z","phase":"Phase 1/2","brief_title":"TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer","source_id_and_acronym":"NCT07044908","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-07-01"},{"id":"38ae3e19-8dad-4b01-a570-b25b5bcb525a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06919666","created_at":"2025-06-21T13:16:45.845Z","updated_at":"2025-06-21T13:16:45.845Z","phase":"Phase 1/2","brief_title":"NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06919666","lead_sponsor":"University of Colorado, Denver","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • NT219"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 02/01/2030","primary_completion_date":" 02/01/2030","study_txt":" Completion: 02/01/2031","study_completion_date":" 02/01/2031","last_update_posted":"2025-06-18"},{"id":"08660c39-94ce-46e6-891f-cb32c681d233","acronym":"","url":"https://clinicaltrials.gov/study/NCT07012954","created_at":"2025-06-14T13:57:24.505Z","updated_at":"2025-06-14T13:57:24.505Z","phase":"Phase 1/2","brief_title":"ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC","source_id_and_acronym":"NCT07012954","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-06-10"},{"id":"17de40db-c7f4-4c4a-854e-574167dd0b13","acronym":"APEAK","url":"https://clinicaltrials.gov/study/NCT06947811","created_at":"2025-06-07T14:40:16.432Z","updated_at":"2025-06-07T14:40:16.432Z","phase":"Phase 1/2","brief_title":"A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations","source_id_and_acronym":"NCT06947811 - APEAK","lead_sponsor":"Sun Yat-sen University","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Ameile (aumolertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 06/09/2025","start_date":" 06/09/2025","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-06-04"},{"id":"ba38e7d6-cf30-459e-86ad-9dab62c47dd9","acronym":"FIRE-11","url":"https://clinicaltrials.gov/study/NCT07004413","created_at":"2025-06-07T14:43:38.689Z","updated_at":"2025-06-07T14:43:38.689Z","phase":"Phase 3","brief_title":"Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients","source_id_and_acronym":"NCT07004413 - FIRE-11","lead_sponsor":"Charite University, Berlin, Germany","biomarkers":" BRAF • CA 19-9","pipe":"","alterations":" ","tags":["BRAF • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 267","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2025-06-04"},{"id":"5561c46c-9fe6-437d-a39f-ed6b0feba556","acronym":"","url":"https://clinicaltrials.gov/study/NCT06998940","created_at":"2025-06-07T14:48:14.371Z","updated_at":"2025-06-07T14:48:14.371Z","phase":"Phase 3","brief_title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","source_id_and_acronym":"NCT06998940","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Vectibix (panitumumab) • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 01/06/2026","start_date":" 01/06/2026","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2025-05-31"},{"id":"c8aaef7c-6714-47f7-9635-9d89ae988ee2","acronym":"LIBRA","url":"https://clinicaltrials.gov/study/NCT06982924","created_at":"2025-09-07T01:40:22.807Z","updated_at":"2025-09-07T01:40:22.807Z","phase":"Phase 2","brief_title":"A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.","source_id_and_acronym":"NCT06982924 - LIBRA","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • limertinib (ASK120067)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-05-21"},{"id":"5dee5c4e-4cac-4602-831a-304102b4edeb","acronym":"CRIT","url":"https://clinicaltrials.gov/study/NCT06908031","created_at":"2025-09-07T01:12:45.769Z","updated_at":"2025-09-07T01:12:45.769Z","phase":"Phase 2","brief_title":"SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer","source_id_and_acronym":"NCT06908031 - CRIT","lead_sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 04/02/2025","start_date":" 04/02/2025","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2025-05-14"},{"id":"0e3b7313-f974-4ff1-8e45-f190a050cd4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06959693","created_at":"2025-09-07T01:30:19.058Z","updated_at":"2025-09-07T01:30:19.058Z","phase":"Phase 2/3","brief_title":"A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)","source_id_and_acronym":"NCT06959693","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Enweida (envafolimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 590","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 09/30/2028","primary_completion_date":" 09/30/2028","study_txt":" Completion: 06/30/2030","study_completion_date":" 06/30/2030","last_update_posted":"2025-05-06"},{"id":"53796a59-6a92-429e-a054-ab12ec9e66b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT06855849","created_at":"2025-06-07T15:05:19.495Z","updated_at":"2025-06-07T15:05:19.495Z","phase":"Phase 2","brief_title":"An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.","source_id_and_acronym":"NCT06855849","lead_sponsor":"Yonsei University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • Rybrevant (amivantamab-vmjw) • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-03-04"},{"id":"17d5dfd7-684d-4f90-850e-e14953c32f5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04091867","created_at":"2021-01-18T20:01:30.016Z","updated_at":"2025-02-25T12:37:25.866Z","phase":"Phase 1","brief_title":"sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC","source_id_and_acronym":"NCT04091867","lead_sponsor":"University of Colorado, Denver","biomarkers":" EPHB4","pipe":" | ","alterations":" EGFR expression • CDKN2A negative","tags":["EPHB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • carboplatin • sEphB4-HSA"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 01/06/2020","start_date":" 01/06/2020","primary_txt":" Primary completion: 05/14/2021","primary_completion_date":" 05/14/2021","study_txt":" Completion: 10/25/2022","study_completion_date":" 10/25/2022","last_update_posted":"2025-02-24"},{"id":"2155cc55-44be-403d-a3c7-183b3abe530b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05638295","created_at":"2022-12-06T16:58:31.646Z","updated_at":"2025-02-25T12:29:13.134Z","phase":"Phase 2","brief_title":"Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)","source_id_and_acronym":"NCT05638295","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS","pipe":"","alterations":" ","tags":["HER-2 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • Lumakras (sotorasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"e7f1cf47-55e5-465b-a0d2-cff0dfd74a56","acronym":"","url":"https://clinicaltrials.gov/study/NCT03191149","created_at":"2021-01-18T15:44:05.558Z","updated_at":"2025-02-25T12:26:43.341Z","phase":"Phase 2","brief_title":"Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change","source_id_and_acronym":"NCT03191149","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-1 • CTLA4","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 04/25/2018","start_date":" 04/25/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-24"},{"id":"06f9902f-3398-49ea-bdd4-ce2518db4d3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04886531","created_at":"2021-05-14T12:52:33.790Z","updated_at":"2025-02-25T13:49:09.000Z","phase":"Phase 2","brief_title":"Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers","source_id_and_acronym":"NCT04886531","lead_sponsor":"Ruth O'Regan","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Nerlynx (neratinib) • letrozole • anastrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/21/2022","start_date":" 07/21/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-21"},{"id":"ae6dde76-a9e2-4ffe-85b4-d60ff795f82d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03919292","created_at":"2021-01-18T19:17:11.532Z","updated_at":"2025-02-25T13:48:40.499Z","phase":"Phase 1/2","brief_title":"Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca","source_id_and_acronym":"NCT03919292","lead_sponsor":"Virginia Commonwealth University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • RAS mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-21"},{"id":"0dde1fb8-86ca-42a7-8591-8335a74747cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT00045201","created_at":"2021-01-18T00:03:58.280Z","updated_at":"2025-02-25T13:51:49.237Z","phase":"Phase 1","brief_title":"Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT00045201","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["EGFR • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • irinotecan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/13/2002","start_date":" 06/13/2002","primary_txt":" Primary completion: 09/13/2013","primary_completion_date":" 09/13/2013","study_txt":" Completion: 08/22/2025","study_completion_date":" 08/22/2025","last_update_posted":"2025-02-20"},{"id":"34e7c443-a4b5-4fa2-810c-e931f9bf2ab9","acronym":"SGNEGFRd2-001","url":"https://clinicaltrials.gov/study/NCT05983133","created_at":"2023-08-09T14:09:24.911Z","updated_at":"2025-02-25T13:55:26.636Z","phase":"Phase 1","brief_title":"A Study of SGN-EGFRd2 in Advanced Solid Tumors","source_id_and_acronym":"NCT05983133 - SGNEGFRd2-001","lead_sponsor":"Seagen Inc.","biomarkers":" EGFR • ALK • MSI","pipe":" | ","alterations":" EGFR mutation • MSI-H/dMMR • ALK rearrangement","tags":["EGFR • ALK • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MSI-H/dMMR • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PF-08046052"],"overall_status":"Recruiting","enrollment":" Enrollment 275","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 09/30/2028","study_completion_date":" 09/30/2028","last_update_posted":"2025-02-20"},{"id":"b7e46662-a1fb-4cfe-bc8c-ef3263bb5749","acronym":"PANIRINOX","url":"https://clinicaltrials.gov/study/NCT02980510","created_at":"2021-01-18T14:39:41.163Z","updated_at":"2025-02-25T13:52:12.814Z","phase":"Phase 2","brief_title":"Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients","source_id_and_acronym":"NCT02980510 - PANIRINOX","lead_sponsor":"UNICANCER","biomarkers":" KRAS • RAS","pipe":"","alterations":" ","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 219","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-20"},{"id":"f99d43e2-a88e-46e7-9ba6-67aaeb1cdec6","acronym":"RTOG 1216","url":"https://clinicaltrials.gov/study/NCT01810913","created_at":"2021-01-18T08:01:55.190Z","updated_at":"2025-02-25T13:52:01.448Z","phase":"Phase 2/3","brief_title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","source_id_and_acronym":"NCT01810913 - RTOG 1216","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • CD4","pipe":" | ","alterations":" CDKN2A negative","tags":["EGFR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • docetaxel • Datalai (cetuximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 613","initiation":"Initiation: 03/22/2013","start_date":" 03/22/2013","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-20"},{"id":"1a0f9386-4e8b-4cdd-9e39-8af1012d0af9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05215548","created_at":"2022-02-05T18:27:48.529Z","updated_at":"2025-02-25T14:08:36.534Z","phase":"Phase 2","brief_title":"Primary Tumor Resection With EGFR TKI for Stage IV NSCLC","source_id_and_acronym":"NCT05215548","lead_sponsor":"National Taiwan University Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/27/2021","start_date":" 09/27/2021","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-02-19"},{"id":"5895dd46-f4f2-46c6-9499-4596f2c29417","acronym":"","url":"https://clinicaltrials.gov/study/NCT06011772","created_at":"2023-08-25T15:08:32.780Z","updated_at":"2025-02-25T14:03:46.296Z","phase":"Phase 1","brief_title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06011772","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" KRAS • BRAF • RAS","pipe":" | ","alterations":" BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type","tags":["KRAS • BRAF • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • CimaVax EGF (EGF-PTI)"],"overall_status":"Suspended","enrollment":" Enrollment 42","initiation":"Initiation: 12/04/2023","start_date":" 12/04/2023","primary_txt":" Primary completion: 12/04/2025","primary_completion_date":" 12/04/2025","study_txt":" Completion: 12/04/2026","study_completion_date":" 12/04/2026","last_update_posted":"2025-02-19"}]